The Correlation between Serum Vitamin D with Apo B and Framingham Risk Score among a Group of Iraqi Subjects: A Cross-sectional and Prospective Pilot Study

Severe Vitamin D correction and prospective measurements of serum Apolipoprotein B and FRS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250301003

Enrollment

100

Registered

2025-03-01

Start date

2022-10-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe vitamin D deficiency, Its correlation with apoliprotein B and Framingham Risk Score vitamin D, Apolipoprotein B, Framingham Risk Score, vitamin D correction

Interventions

Correction of severe vitamin D deficiency 10ng/mL and less in the treatment group of 60 participants (oral tablet of vitamin D 50000 IU for 8 weeks followed by a maintenance dose of 1000 IU/day for 16

Experimental Other,No Intervention No treatment

oral vitamin D supplementations,Control group/no intervention just follow up

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Severe serum vitamin D deficiency and vitamin D sufficiency 2. Aged 30 years and above 3. No history of CVD except for hypertension 4. No treatment except for hypertension 5. Accepted to participate and sign the consent form

Exclusion criteria

Exclusion criteria: 1. Chronic or acute illness 2. Pregnant and breast-feeding women

Design outcomes

Primary

Measure	Time frame
vitamin D correction 6 months laboratory examination	—

Secondary

Measure	Time frame
measurements of serum apolipoprotein B and FRS 6 months laboratory examination	—

Countries

Iraq

Contacts

Public ContactIsraa Ahmed

Universiti Sains Malaysia

israa83@gmail.com07811918598

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026